Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 3/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737078 | 0.84 | CRBN (0.38) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL8082419 | 0.81 | CRBN (0.44) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL20223130 | 0.81 | CRBN (0.44) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL24519704 | 0.79 | CRBN (0.38) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL22751156 | 0.79 | CRBN (0.38) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL18938260 | 0.78 | CRBN (0.41) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL19370324 | 0.76 | CRBN (0.38) | CRBNALDH1A1PTGS1 | |
| SCHEMBL22751157 | 0.76 | CRBN (0.30) | CRBN | |
| SCHEMBL12040069 | 0.76 | CRBN (0.30) | CRBN | |
| SCHEMBL20956950 | 0.75 | CRBN (0.42) | CRBNTOP2ATOP2BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0759475-B1 | Method for the production of (R)-ter-leucine | DEGUSSA (DE) | 1999-08-25 | — | — | EP | claimed |
| JP-9103297-A | — | — | None | — | — | JP | disclosed |
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-6100424-A | Process for the preparation of amino acetic acid esters with a tertiary hydrocarbon radical in the α-position | DEGUSSA-HUELS AKTIENGESELLSCHAFT (DE) | 2000-08-08 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0970944-A1 | Preparation of amino acetic acid esters substituted at position alpha by a tertiary hydrocarbon chain | Degussa-Hüls Aktiengesellschaft (DE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0759475-B1 | Method for the production of (R)-ter-leucine | DEGUSSA (DE) | 1999-08-25 | — | — | EP | disclosed |
| US-5707837-A | Method of producing (R)-tertiary leucine | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1998-01-13 | — | — | US | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| JP-H09103297-A | PRODUCTION OF (R)-T-LEUCINE | DEGUSSA AG | 1997-04-22 | — | — | JP | disclosed |
| EP-0759475-A1 | Method for the production of (R)-ter-leucine | DEGUSSA AG (DE) | 1997-02-26 | — | — | EP | disclosed |
| EP-0759475-A1 | Method for the production of (R)-ter-leucine | DEGUSSA AG (DE) | 1997-02-26 | — | — | EP | disclosed |
| EP-0160618-B1 | HYDANTOIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | CRBN 3693/4885TOP2A 13/4885TOP2B 20/4885 |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | P2RX7, P2RX3, P2RX5 | CRBN 3117/4885TOP2A 4255/4885TOP2B 2701/4885 |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, THRA, TSHR | CRBN 4766/4885TOP2A 3589/4885TOP2B 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.